Conferences

24th Int'l. Prostate Cancer Update

February 19 - 22, 2014

Cascade Conference Center
Vail, Colorado USA

Society of Urodynamics, Female Pelvic Medicine
and Urogenital Reconstruction (SUFU) Winter Meeting

February 25 - March 1, 2014

Doral Golf Resort and Spa
Miami, Florida USA

78th Annual Meeting of the
Southeastern Section of the AUA
March 20 - 23, 2014

Hollywood, FL USA

29th Annual European Association
of Urology (EAU) Congress
April 11 - 15, 2014

Stockholm, Sweden

American Urological Association (AUA)
Annual Meeting
May 16 - 21, 2014

Orlando, Florida USA

American Society of Clinical Oncology (ASCO)
2014 Annual Meeting

May 30 - June 3, 2014

McCormick Place
Chicago, IL USA

American Urogynecologic Society (AUGS) and
the International Urogynecological Association (IUGA)
Joint Scientific Meetings

July 22 - 26, 2014

Washington, DC USA

32nd World Congress of Endourology & SWL

September 3 - 7, 2014

Taipei, Taiwan

2014 Winter Meeting of the Society of Urologic Oncology (SUO)

"Defining Excellence in Urologic Oncology"

December 3 - 5, 2014
Bethesda, MD USA

 

 

#SUO14 - Session Highlights: Nerve sparing and template choice

 

#SUO14 - Session Highlights: Choice of templates for low-stage testis cancer

 

#SUO14 - Session Highlights: Minimizing morbidity of RPLND

 

#SUO14 - Session Highlights: The role of SETD2 mutations in the biology of renal cell carcinoma

 

#SUO14 - Session Highlights: Therapy of kidney cancer: Where are we going next?

 

#SUO14 - Session Highlights: Impact of systemic therapy on characterization of peripheral circulating tumor cells in metastatic renal cell carcinoma

 

#SUO14 - Session Highlights: Accelerated growth rate of multifocal tumors after initial radiofrequency ablation

 

#SUO14 - Session Highlights: FSH and the metabolic syndrome

 

#SUO14 - Session Highlights: Non-genomic AR pathway

 

#SUO14 - Session Highlights: What is the impact of ECOG 3805 (CHAARTED) results on clinical practice?

 

#SUO14 - Session Highlights: Sequencing prior to chemotherapy

 

#SUO14 - Session Highlights: Cystectomy enhanced recovery pathway: Reduction in length of stay without increased morbidity or readmission

 

#SUO14 - Session Highlights: Declining rate of prostate biopsy in the Veterans Health Administration in the past decade: An alternate approach to limiting overdiagnosis and overtreatment of prostate cancer?

 

#SUO14 - Session Highlights: Role of 18-FDG PET/CT in staging of penile/urethral squamous cell carcinoma

 

#SUO14 - Session Highlights: Trends in utilization, perioperative outcomes, and costs among open, laparoscopic, and robotic nephroureterectomies: A 10-year population-based analysis

 

#SUO14 - Abstract and Poster: Decline in the use of radiation for stage I seminoma: Analysis of the National Cancer Database

 

#SUO14 - Abstract and Poster: Receipt of inguinal lymph node dissection in patients with T2 penile cancer: Results from the National Cancer Database

 

#SUO14 - Session Highlights: Next generation sequencing of DNA from urine detects multiple bladder tumor-derived alterations and additional changes that suggest tumor heterogeneity

 

#SUO14 - Session Highlights: Is a 12-core biopsy of any value in patients with a previous negative prostate biopsy and visible lesion on magnetic resonance imaging?

 

#SUO14 - Session Highlights: Histology vs. genomics: Does Gleason 3 have the hallmarks of cancer?

 

#SUO14 - Session Highlights: Should MR be the standard of care before biopsy?

 

#SUO14 - Session Highlights: Imaging for biochemical recurrence

 

#SUO14 - Session Highlights: Long-term adverse effects in testicular cancer survivors

 

#SUO14 - Session Highlights: What a urologist should do based upon long-term side effects of chemotherapy

 

#SUO14 - Session Highlights: New approaches to chemotherapy in bladder cancer

 

#SUO14 - Session Highlights: Management of locally advanced renal cell carcinoma and management of the adrenal gland

 

#SUO14 - Session Highlights: Role of lymph node dissection in advanced RCC

 

#SUO14 - Session Highlights: Management of IVC thrombi

 

#SUO14 - Session Highlights: Checkpoint targeted immunotherapy

 

#SUO14 - Session Highlights: The role of neoadjuvant therapy in kidney cancer patients

 

#SUO14 - Session Highlights: Role of surgery for nodal oligometastatic disease in men with biochemical failure

 

#SUO14 - Session Highlights: Role of post-op RT for pN+ after prostatectomy

 

#SUO14 - Session Highlights: Radical prostatectomy for oligometastatic disease

 

#SUO14 - Session Highlights: Targeting hormone-DNA repair crosstalk in prostate cancer: Implications for disease progression and therapeutic intervention

 

#SUO14 - Session Highlights: Targeting PD-1 and PD-L1 in bladder cancer 

 

#SUO14 - Session Highlights: Clinical trials of novel targeted agents

 

#SUO14 - Abstract and Poster: Neoadjuvant chemotherapy is not associated with increased risk of perioperative complications, mortality, nor readmission rates in patients undergoing radical cystectomy

 

#SUO14 - Abstract and Poster: Declining rates of retroperitoneal lymph node dissection for stage I non-seminomatous germ cell tumors: Results from the National Cancer Database

 

#SUO14 - Session Highlights: Declining rates of retroperitoneal lymph node dissection for stage I non-seminomatous germ cell tumors: Results from the National Cancer Database

 

#SUO14 - Abstract and Poster: Surgical Apgar score predicts an increased risk for death and readmission following radical cystectomy

 

#SUO14 - Abstract and Poster: Surgical Apgar score and nephrometry score predict increased risk for major complication and death following renal mass excision

 

#SUO14 - Session Highlights: New insights into bladder cancer subtyping

 

#SUO14 - Session Highlights: Genetic findings in invasive bladder cancer: Recent Data and clinical implications

 

#SUO14 - Session Highlights: Epigenetic control of bladder cancer heterogeneity by non-coding RNAs

 

#SUO14 - Session Highlights: Towards a molecular genetic and functional classification of renal cancer

 

#SUO14 - Session Highlights: Biology of bladder cancer metastasis

 

#SUO14 - Session Highlights: Challenges and opportunities facing tumor and therapeutic heterogeneity of kidney cancer

 

#SUO14 - Session Highlights: RCC tumor ontogeny – lessons from the small renal mass

 

#SUO14 - Session Highlights: Optimal targeting of the PD-1/PDL-1 pathway in metastatic renal cell carcinoma

 

Genitourinary Cancers Symposium 2015

February 26 - 28, 2015

Rosen Shingle Creek
Orlando, FL USA

 

 

 #GU15 - Androgen deprivation therapy, cardiovascular risk, and multidisciplinary management of the prostate cancer patient: A German perspective - Session Highlights

 

#GU15 - AR splice variant 7 (AR-V7) could be a marker for treatment selection in metastatic castrate-resistant prostate cancer

 

#GU15 - Novel imaging modalities boost detection of early metastatic disease in prostate cancer - Session Highlights

 

#GU15 - Progress and challenges in penile, urethral, and testicular cancer - Session Highlights

 

#GU15 - Prostate cancer in 2014- 2015: Advances and ongoing challenges in therapeutics, biomarkers, and precision medicine

 

#GU15 - Renal cell cancer keynote: Management of RCC: Future needs and opportunities - Session Highlights

 

#GU15 - Year in review: Renal cell cancer - Session Highlights

 

#GU15 - Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial - Session Highlights

 

#GU15 - Metabolic pathways - Session Highlights

 

#GU15 - Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy (NAC) in urothelial carcinoma - Session Highlights

 

#GU15 - Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience - Session Highlights

 

#GU15 - Correlation of baseline serum testosterone and PSA at 7 months in patients with new metastatic prostate cancer treated with continuous ADT - Session Highlights

 

#GU15 - Treatment patterns of new metastatic castration-resistant prostate cancer (mCRPC) therapies: Real-world evidence from three datasets - Session Highlights

 

#GU15 - AR modulation optimized for response in splice variant (ARMPR3-SV): A RCT of galeterone vs enzalutamide in men expressing ARv7 in mCRPC - Session Highlights

 

#GU15 - Poster: Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel subgroup

 

#GU15 - Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel subgroup - Session Highlights

 

#GU15 - Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting - Session Highlights

 

#GU15 - Radium-223 dichloride (Ra-223) in U.S. Expanded Access Program (EAP) - Session Highlights

 

#GU15 - Association between PSA declines at 4 weeks and OS in patients treated with abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC) after docetaxel - Session Highlights

 

#GU15 - Effect of early detection of asymptomatic visceral recurrence after radical cystectomy on prognosis in patients with muscle invasive bladder cancer - Session Highlights

 

#GU15 - Effect of early detection of asymptomatic visceral recurrence after radical cystectomy on prognosis in patients with muscle invasive bladder cancer - Session Highlights

 

#GU15 - Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone - Session Highlights

 

#GU15 - Urothelial carcinoma keynote - Session Highlights

 

#GU15 - Exploring the effects of abiraterone/enzalutamide failure prior to the initiation of radium-223 dichloride in men with metastatic castrate-resistant prostate cancer - Session Highlights

 

#GU15 - The impact of time to metastasis on survival in treatment-naïve prostate cancer patients - Session Highlights

 

#GU15 - A multidisciplinary clinic to mitigate the impact of androgen deprivation therapy in prostate cancer: A pilot study - Session Highlights

 

#GU15 - Contemporary use of radium-223 (Ra-223) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Feasibility and safety - Session Highlights

 

#GU15 - Best of journals: mCRPC treatment - Session Highlights

 

#GU15 - Urothelial carcinoma: Year in review - Session Highlights

 

#GU15 - The biology of bladder cancer metastasis - Session Highlights

 

#GU15 - What is new in systemic therapy for urothelial tumors? - Session Highlights

 

#GU15 - Best of journals: Prostate cancer - Session Highlights

 

#GU15 - Best of journals - Session Highlights

 

#GU15 - Dynamic changes in biomarkers for immune response to sipuleucel-T for mCRPC - Session Highlights

 

#GU15 - FANCA loss as a biomarker of platinum sensitivity in prostate cancer - Session Highlights/span>

 

#GU15 - Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014 - Session Highlights

 

#GU15 - Are patients with Gleason 6 pathology safe from developing metastatic castration-resistant prostate cancer (mCRPC)? - Session Highlights

 

#GU15 - Testosterone levels in metastatic castration resistant prostate cancer (mCRPC) - Session Highlights

 

#GU15 - Poster: 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA

  

#GU15 - 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA - Session Highlights

 

#GU15 - Place of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy: A phase III trial - Session Highlights

 

#GU15 - Prostate Cancer Keynote: Can epigenetic alterations in human cancers be exploited for cancer screening, detection, diagnosis and treatment? - Session Highlights

 

#GU15 - Prostate cancer: Year in review - Session Highlights

 

#GU15 - ASCENDE-RT: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer - Session Highlights

 

#GU15 - ADT plus docetaxel versus ADT alone for hormone-naïve metastatic prostate cancer: Long-term analysis of the GETUG-AFU 15 phase III trial - Session Highlights

 

#GU15 - Characterization of abiraterone responses in African American men with castrate resistant prostate cancer - Session Highlights

 

#GU15 - Effects of radium-223 dichloride with docetaxel (D) versus D on PSA and bone alkaline phosphatase in patients with castration-resistant prostate cancer and bone metastases: A phase 1/2a clinical trial - Session Highlights

 

#GU15 - Poster: Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302

 

#GU15 - Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302 - Session Highlights

 

#GU15 - Poster: External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial

 

#GU15 - External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial - Session Highlights

 

#GU15 - Quantitative total bone imaging (QTBI) in patients with metastatic castration-resistant prostate cancer (CRPC) using NaF PET/CT - Session Highlights

 

#GU15 - AR-based biomarker association with response to abiraterone in mCRPC - Session Highlights

 

#GU15 - Antigen-specific immune responses through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer - Session Highlights

 

#GU15 - Assessment of corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate in mCRPC - Session Highlights

 

#GU15 - Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: Exploratory analysis of a randomized controlled trial - Session Highlights

 

#GU15 - Increase in higher risk prostate cancer cases following new screening recommendation by the US Preventive Services Task Force (USPSTF) - Session Highlights

 

#GU15 - Early radiation response between GnRH agonist versus antagonist combined with radiotherapy in high-risk prostate cancer - Session Highlights

 

#GU15 - Impact of CCP test on personalizing treatment decisions: Results from a prospective registry of newly diagnosed prostate cancer patients - Session Highlights

 

#GU15 - Abstract highlights: AR splice variant 7 (AR-V7) and response to taxanes in men with mCRPC - Session Highlights

 

#GU15 - Bench to bedside: Androgen resistance - Session Highlights

 

#GU15 - Clinical context: Using new imaging modalities to identify early metastatic disease - Session Highlights

 

#GU15 - Role of local therapy - Session Highlights

 

#GU15 - A multi-institutional prospective trial in the United States confirms the 4K Score accurately identifies men with high-grade prostate cancer - Session Highlights

 

#GU15 - Biomarkers for prostate cancer: Why aren’t we using them and where do we go from here? - Session Highlights

 

#GU15 - Hormonal therapy: How long is enough? - Session Highlights

 

#GU15 - Who can receive shorter-course radiotherapy? Hypofractionation and stereotactic body radiation therapy - Session Highlights

 

#GU15 - Individualized treatment decisions for localized prostate cancer: Decision aids and quality of life outcomes - Session Highlights

 

Bayer presents latest oncology research at ASCO GU 2015

 

Early evidence of increase in higher-risk prostate cancers from 2011-2013

 

Active surveillance of intermediate-risk prostate cancer associated with decreased survival

 

Men who have had testicular cancer are more likely to develop prostate cancer, although overall risk of developing aggressive disease is low

 

 

Adjuvant sorafenib and sunitinib do not improve outcomes in locally advanced kidney cancer

 

 

Androgen receptor abnormality may not be associated with primary resistance to taxane chemotherapy

 

 

 

American Urological Association (AUA)
Annual Meeting
May 15 - 19, 2015

New Orleans, Louisiana USA

American Society of Clinical Oncology (ASCO)
2015 Annual Meeting

May 29 - June 2, 2015

McCormick Place
Chicago, IL USA

Winter Meeting of the Society of Urologic Oncology (SUO)

"Defining Excellence in Urologic Oncology"

December 2 - 4, 2015
Washington, DC USA